Asia
Shuangcheng Pharmaceuticals Secures License Amendment for Hydrochloride Tablets
Hainan Shuangcheng Pharmaceuticals (SHE:002693) unit Ningbo Shuangcheng obtained an amended drug manufacturing license from the Zhejiang regulator.The amendment added Guangzhou Jiurui Pharmaceutical as an entrusted manufacturer for memantine hydrochloride tablets, according to a Tuesday filing with the Shenzhen bourse.The license remains valid until Nov. 13, 2027, with no other changes.Shares of the pharmaceutical company closed 5% lower Tuesday.
SHE:002693
